262 results on '"Kostakoglu L"'
Search Results
2. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
3. An automated quantification algorithm for evaluating total metabolic tumor volume in patients with FDG‐avid lymphomas using a deep learning model
4. Hodgkin’s Disease and Lymphomas
5. Additional file 1 of Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
6. The potential value and pitfalls of radiomics for clinical positron emission tomography (PET) in DLBCL: a comparison between two of most widely used segmentation thresholds
7. Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
8. CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)
9. PET-CR AS A SURROGATE FOR SURVIVAL OUTCOMES IN DLBCL: A LITERATURE BASED META-ANALYSIS
10. BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL
11. RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY
12. ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP
13. S1598 BASELINE TOTAL METABOLIC TUMOR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL
14. Application of 18-F Fluciclovine PET/CT in Guiding Salvage Radiation Therapy for Recurrent Prostate Cancer
15. OL35 - The potential value and pitfalls of radiomics for clinical positron emission tomography (PET) in DLBCL: a comparison between two of most widely used segmentation thresholds
16. Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma
17. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using F-18-FMISO PET and MRI
18. Patterns of Oropharyngeal Cancer Failure Detection in the HPV Era
19. Feasibility of Integrated PET/MRI and PET/CT Imaging for Gynecological Malignancies
20. Recurrence Patterns in HPV-Positive Oropharyngeal Cancers and Implications for Long-Term Surveillance Imaging
21. END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY
22. Diagnostic Medical Radiation Exposure in Surveillance of Aggressive Lymphoma: Clinical Trial Design Should Reflect Clinical Practice Reply
23. Fallacy of Quantifying Lymphoma Activity by Scaling to the Liver in [F-18] Fluorodeoxyglucose Positron Emission Tomography (Deauville criteria) Reply
24. Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy
25. Hodgkin’s Disease and Lymphomas
26. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury
27. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
28. Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?
29. OT2-05-03: ACRIN 6688 Phase II Study of Fluorine-18 3′-Deoxy-3′ Fluorothymidine (FLT) in Invasive Breast Cancer.
30. ACRIN 6688 phase II study of fluorine-18 3′-deoxy-3′ fluorothymidine (FLT) in invasive breast cancer.
31. Preliminary data from an ongoing phase IIb study of no carrier added 131I-iobenguane (nca-MIBG) in patients with malignant pheochromocytoma (Pheo).
32. Use of combined FDG-PET and laboratory data for predicting relapse in multiple myeloma.
33. Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma.
34. The Significance and Management of Incidental [18F]Fluorodeoxyglucose–Positron-Emission Tomography Uptake in the Thyroid Gland in Patients with Cancer
35. High Uptake in Schneiderian Papillomas of the Maxillary Sinus on Positron-Emission Tomography Using Fluorodeoxyglucose
36. Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma
37. Correlation of PET Standard Uptake Value and Pathologic Specimen Size in Cancer of the Head and Neck
38. Prediction of response to therapy with clarithromycin/lenalidomide/dexamethasone (BIRD) in multiple myeloma using FDG-PET
39. FDG-PET predicts disease burden in multiple myeloma
40. FDG-PET versus Thallium-201 SPECT in the evaluation of putative CNS lymphoma in AIDS patients
41. Tositumomab and iodine I 131 tositumomab: Efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin’s lymphoma (NHL)
42. Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL)
43. A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with > 25% bone marrow involvement
44. Hodgkin's Disease and Lymphomas.
45. 90Y-DOTA-lanreotide: Dosimentry and toxicity
46. Altered cerebral blood flow in patients with conversion disorders
47. TI-201 Uptake in Recurrent Pigmented Villonodular Synovitis: Correlation with Three-phase Bone Imaging
48. The Relationship between Thallium Uptake, Blood Flow, and Blood Pool Activity in Bone and Soft Tissue Tumors
49. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer.
50. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.